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Abstract	
The	 nature	 of	mental	 illness	 remains	 a	 conundrum.	 Traditional	 disease	 categories	 are	 increasingly	
suspected	 to	 mis-represent	 the	 causes	 underlying	 mental	 disturbance.	 Yet,	 psychiatrists	 and	
investigators	 now	 have	 an	 unprecedented	 opportunity	 to	 benefit	 from	 complex	 patterns	 in	 brain,	
behavior,	and	genes	using	methods	 from	machine	 learning	 (e.g.,	 support	vector	machines,	modern	
neural-network	algorithms,	cross-validation	procedures).	Combining	these	analysis	techniques	with	a	
wealth	of	data	from	consortia	and	repositories	has	the	potential	to	advance	a	biologically	grounded	
re-definition	of	major	psychiatric	disorders.	Within	the	next	10-20	years,	incoming	patients	could	be	
stratified	 into	distinct	biological	subgroups	that	cut	across	classical	diagnostic	boundaries.	 In	a	new	
era	of	evidence-based	psychiatry	tailored	to	single	patients,	objectively	measurable	endophenotypes	
could	 allow	 for	 individualized	 prediction	 of	 early	 diagnosis,	 treatment	 selection,	 and	 dosage	
adjustment	to	reduce	the	burden	of	disease.	This	primer	aims	to	introduce	clinicians	and	researchers	
to	the	opportunities	and	challenges	in	bringing	machine	intelligence	into	psychiatric	practice.	
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Introduction	
	
By	 relying	 on	 human-conceived	 diagnostic	 groups,	 psychiatric	 treatment	 is	 explored	 in	 scientific	
research,	 evaluated	 for	 effectiveness	 in	 clinical	 trials,	 and	 administered	 every	 day	 to	 suffering	
patients.	 These	 pervasively	 adopted	 diagnostic	 categories	 have	 been	 constructed	 from	 expert	
opinion	and	enshrined	in	the	DSM-5	and	ICD-10	manuals.	Yet,	 it	 is	becoming	increasingly	clear	that	
the	pathophysiology	underlying	 such	disease	definitions	 is	 rather	 heterogeneous	 (1,	 2).	 A	 clinically	
distinct	mental	disease	 is	often	not	underpinned	by	an	 identical	biology	as	 far	as	we	can	detect	by	
available	 neuroscientific	 instruments.	 This	 frustration	 can	 potentially	 be	 alleviated	 by	 identifying	
subgroups	that	exhibit	predictable	response	to	treatment.	The	aspiration	to	automatically	segregate	
brain	disorders	into	natural	kinds	will	however	necessitate	new	statistical	and	scientific	approaches.	
For	 decades,	 the	 dominant	 research	 paradigm	 to	 alleviate	 symptoms	 of	 psychiatric	 patients	 has	
followed	 an	 ideal	 chain	 of	 events:	 1)	 initially	 neuroscience	 studies	 should	 identify	 new	 disease	
mechanisms	(e.g.,	neurotransmitter	pathways	in	animal	models),	2)	then	novel	treatments	should	be	
explored	 to	 target	 the	 discovered	 disease	mechanisms	 (e.g.,	 design	 and	 test	 candidate	molecular	
compounds),	and	3)	 finally	 the	new	treatment	should	be	validated	by	clinical	 trials	 in	 large	cohorts	
(e.g.,	 randomized	 clinical	 drug	 trials).	 Despite	 numerous	 important	 advances,	 each	 of	 these	 three	
steps	has	encountered	considerable	difficulties.	
First,	the	search	for	novel	disease	mechanisms	has	yielded	sobering	results	in	many	mental	diseases	
(3,	4).	A	contributing	 reason	may	be	 that	animal	models	of	psychiatric	disorders	 typically	 immitate	
some	 properties	 of	 a	 given	 brain	 disorder	 without	 emulating	 the	 disorder	 itself	 (5).	 Second,	 over	
recent	years,	major	players	 in	the	pharmaceutical	 industry	have	been	abandoning	their	 investment	
programs	 for	 psychotropic	 drug	 discovery	 (6).	 This	 trend	 can	 be	 observed	 in	 the	 USA	 (Pfizer	 and	
Merck),	 Switzerland	 (Novartis),	 France	 (Sanofi),	 and	 UK	 (GlaxoSmithKline	 and	 AstraZeneca).	 As	 a	
consequence,	innovative	drug	treatments	become	even	less	likely	to	enter	the	market	in	the	next	10	
to	20	years.	Third,	it	is	often	only	in	later	stages	of	the	numbingly	expensive	clinical	trials	that	many	
psychotropic	drug	candidates	turn	out	to	be	ineffective	or	not	usable	in	humans	(7,	8).	In	wanting	to	
supplement	this	 traditional	paradigm	 in	psychiatric	 research,	modern	machine	 learning	approaches	
probably	 lend	 themselves	 particularly	 well	 to	 ultimately	 improve	 the	 well-being	 of	 psychiatric	
patients.	
Machine	 learning	 uses	 quantitative	 models	 to	 induce	 general	 principles	 underlying	 a	 series	 of	
observations	without	explicit	 instructions	(9,	10).	Such	algorithmic	methods	are	characterized	by	1)	
making	few	a-priori	assumptions,	2)	allowing	the	data	to	“speak	for	themselves”,	and	3)	the	ability	to	
mine	 structured	knowledge	 from	extensive	data.	 Its	members	 include	supervised	methods,	such	as	
support	 vector	 machines	 and	 neural-network	 algorithms,	 specialized	 for	 best-possible	 outcome	
prediction	as	well	as	unsupervised	methods,	such	as	algorithms	for	data	clustering	and	dimensionality	
reduction,	effective	at	discovering	novel	 statistical	 configurations	 in	data	 (see	Table	1	 for	 technical	
terms).	 The	 recent	 coincidence	 of	 increasing	 data	 availability,	 improving	 computing	 power,	 and	
cheaper	 data	 storage	 has	 encouraged	 an	 ongoing	 surge	 in	 research	 and	 applications	 of	 machine	
learning	 technologies	 roughly	since	 the	 turn	of	 the	century,	although	a	majority	of	 these	 tools	had	
already	emerged	in	the	second	half	of	the	20th	century	(11).	Here,	input	versus	output	variables	for	
quantitative	 modeling	 are	 called	 "features"	 versus	 “target	 variables”	 (12),	 familiar	 to	 many	 as	
independent	 versus	 dependent	 variables.	 As	 another	 special	 property,	 inferring	 new	 domain	
knowledge	 routinely	 takes	 the	 empirical	 form	 of	 extrapolating	 patterns	 by	 successfully	 predicting	
information	 about	 previously	 unseen	 observations	 in	 cross-validation	 procedures	 (13).	 In	 the	
following	we	will	argue	that	machine	learning	is	predisposed	to	address	many	upcoming	challenges	
in	the	era	of	precision	medicine	in	psychiatry.	
	
Opportunities	
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Current	drug	treatment	choices	are	only	successful	in	roughly	every	second	patient	(14),	and	similar	
considerations	apply	to	psychotherapy.	An	alternative	research	strategy	that	does	not	depend	on	full	
understanding	of	complex	disease	mechanisms	may	 therefore	be	cheaper	and	 incur	 shorter	delays	
between	 bench	 and	 beside	 (15).	 Indeed,	 the	 psychiatrist's	 choice	 of	 the	 best-possible	 treatment	
option	often	does	not	depend	on	knowledge	of	what	has	caused	or	maintains	the	mental	disease	of	a	
given	patient.	Systematically	benchmarking	the	predictability	of	clinical	quantities	 in	single	patients	
could	 faster	 improve	 clinical	 symptoms	 and	 reduce	 subjective	 suffering	 in	 many	mental	 diseases.	
Even	moderately	successful	predictive	models	can	be	highly	useful	in	clinical	practice.	This	is	because	
of	the	unfortunate	normal	case	of	trial-and-error	treatment	with	psychotropic	drugs	and	other	types	
of	 treatment	 for	many	mental	 diseases	 (16).	While	 the	 traditional	 research	 goal	was	 to	 introduce	
novel	 treatment	options	 that	 benefits	 some	majority	 of	 the	 respective	 clinical	 group,	 an	 attractive	
alternative	 research	goal	 is	 to	 improve	 the	choice	of	existing	 treatment	options	by	predicting	 their	
effectiveness	in	single	patients.	
Psychiatric	 research	 has	 long	 been	 at	 odds	 with	 conventions	 in	 clinical	 practice.	 A	 disconnect	 is	
apparent	 between	medical	 training	 ingrained	 in	 diagnostic	 categories	 and	 qualitative	medical	 care	
idiosyncratic	 to	particular	 individuals.	Even	 if	clinical	guidelines	are	typically	backed	up	by	scientific	
results	 on	 group	 effects,	 psychiatrists	 frequently	 act	 on	 a	 patient-by-patient	 basis	 on	 the	ward.	 In	
contrast	to	other	medical	specialties,	 treatment	choice	 in	psychiatry	 is	 to	a	 larger	extent	guided	by	
symptoms	 and	 phenomenology	 of	 a	 particular	 patient,	 rather	 than	 exclusively	 dictated	 by	 the	
patient’s	 diagnosis.	However,	 scarce	evidence	exists	 to	 reduce	 the	uncertainty	of	which	 treatment	
will	benefit	which	patient.	No	objective	biomarkers,	be	they	derived	from	blood,	brain,	or	genes,	are	
currently	 available	 for	 treatment	 outcome	 prediction	 in	 psychiatric	 patients,	 incurring	 social	 crisis,	
life-quality	 costs,	 and	 socioeconomic	 burden.	More	 and	more	 studies	 now	 indicate	 that	 a	 specific	
drug	or	psychotherapy	treatment	can	be	successful	in	a	certain	patient	subgroup	and	unsuccessful	in	
another	 patient	 subgroup	 labeled	with	 an	 identical	 diagnosis	 (see	 here	 for	 an	 overview:	 17).	 In	 a	
seminal	 machine	 learning	 study,	 discovered	 patient	 subgroup	 could	 indeed	 predict	 which	 patient	
would	 profit	 from	 brain-stimulation	 treatment	 (18).	 This	 questions	 the	 primacy	 of	 drawing	
conclusions	on	the	group-level	and	opens	the	possibility	of	building	objective	algorithmic	frameworks	
with	individual	treatment-response	prediction	across	a	diversity	of	psychiatric	conditions.	
	
Machine	 learning	 offers	 a	 set	 of	 tools	 that	 are	 ideally	 suited	 to	 achieve	 individual-level	 clinical	
predictions.	 Predictive	models	 are	 conceptually	 positioned	 themselves	 between	 clinical	 symptoms	
and	genetic	risk	variants,	which	has	the	translational	potential	to	refine	clinical	management	by	early	
diagnosis	and	disease	stratification,	selection	between	drug	treatments,	treatment	adjustment,	and	
prognosis	for	psychiatric	care	tailored	to	each	individual	(18).	Learning	algorithms	can	thus	be	readily	
applied	in	single	patients	to	predict	inherently	valid	and	immediately	useful	clinical	objects	(19),	such	
as	 choosing	 drug	 dosage.	 There	 is	 a	 number	 of	 reasons	why	many	machine	 learning	methods	 are	
naturally	 applicable	 for	 prospective	 clinical	 predictions	 on	 the	 single-subject	 level,	 whereas	 the	
currently	most	widespred	statistical	methods	may	be	more	tuned	to	group-level	analysis:	
i)	Focus	on	prediction:	Machine	learning	methods	have	always	had	a	strong	focus	on	prediction	as	a	
metric	 of	 statistical	 quality	 (12).	 Support	 vector	 machines,	 neural-network	 algorithms,	 and	 many	
other	predictive	models	 are	hence	 readily	 able	 to	estimate	an	outcome	 from	only	one	data	point,	
such	as	when	querying	answers	from	behavioral,	neural,	or	genetic	measurements	of	a	single	patient	
(20,	 21).	 In	 contrast,	 classical	 statistical	 methods	 are	 often	 used	 in	 medical	 research	 to	 explain	
variance	of	and	formally	test	for	group	effects.	ANOVA,	t-test,	and	many	other	commonly	used	tools	
underlying	 the	 notion	 of	 statistical	 significance	 have	 a	 less	 obvious	 ability	 for	 judgements	 on	 one	
specific	individual	in	a	group.	Thus,	routines	of	machine	learning	and	classical	statistics	serve	rather	
distinct	statistical	purposes.	The	two	statistical	cultures	perform	different	types	of	formal	assessment	
for	 successful	 extrapolation	 of	 an	 effect	 beyond	 the	 data	 at	 hand	 that	 are	 rooted	 in	 different	
mathematical	 contexts.	 As	 an	 important	 practical	 consequence,	 machine	 learning	 and	 classical	
statistics	 do	 not	 judge	 data	 on	 the	 same	 aspects	 of	 evidence:	 An	 observed	 effect	 assessed	 to	 be	
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statistically	 significant	 by	 a	 p-value	 does	 not	 in	 all	 cases	 yield	 high	 prediction	 accuracy	 in	 new,	
independent	data,	and	vice	versa	(10,	21-23).	
	
ii)	Empirical	model	evaluation:	By	quantifying	the	prediction	success	in	new	individuals	(so-called	out-
of-sample	 estimates)	 many	machine	 learning	 approaches	 naturally	 adopt	 a	 prospective	 viewpoint	
and	 can	 directly	 yield	 a	 notion	 of	 clinical	 relevance.	 Instead,	 classical	 approaches	 based	 on	 null-
hypothesis	testing	often	take	a	retrospective	flavor	as	they	usually	revolve	around	finding	statistical	
effects	 in	 the	 dataset	 at	 hand	 (so-called	 in-sample	 estimates)	 based	 on	 a	 pre-specified	 modeling	
assumptions,	 typically	 without	 explicitly	 evaluating	 some	 fitted	 models	 on	 unseen	 or	 future	 data	
points	 (22).	 Hence,	 techniques	 for	 out-of-sample	 generalization	 common	 in	 machine	 learning	 are	
likely	candidates	for	enabling	a	future	of	personalized	psychiatry.	This	 is	because	predictive	models	
can	be	applied	to	and	obtain	answers	from	a	single	patient.	
	
iii)	 Two-step	 procedures:	 Similarly,	 traditional	 null-hypothesis	 testing	 takes	 the	 form	of	 a	one-step	
procedure.	That	is,	the	whole	dataset	is	routinely	used	to	produce	a	p-value	or	effect	size	measure	in	
a	single	process.	An	obtained	p-value	or	effect	size	can	itself	not	be	used	to	judge	other	data	in	some	
later	 step.	 In	 contrast,	 machine	 learning	 models	 are	 typically	 evaluated	 by	 cross-validation	
procedures	as	a	gold	standard	to	quantify	the	capacity	of	a	learning	algorithm	to	extrapolate	beyond	
the	dataset	at	hand	(12).	In	a	two-step	procedure,	a	learning	algorithm	is	fitted	on	a	bigger	amount	of	
available	 data	 (so-called	 "training	 data")	 and	 the	 ensuing	 "trained"	 learning	 model	 is	 empirically	
evaluated	 by	 application	 to	 a	 smaller	 amount	 of	 new	 data	 (so-called	 "test	 data").	 This	 two-step	
nature	 of	 machine	 learning	 workflows	 lends	 itself	 particularly	 well	 to,	 first,	 extract	 structured	
knowledge	 in	 large	 openly	 available	 or	 hospital-provided	 datasets.	 Second,	 the	 ensuing	 trained	
predictive	models	can	be	shared	collaboratively	as	a	research	product	(24)	and	be	applied	with	little	
effort	in	a	possibly	large	number	of	individual	patients	in	various	mental	health	contexts.	
	
iv)	Suited	to	observational	data:	Many	methods	from	classical	statistics	have	probably	been	devised	
for	 experimental	 data	 that	 are	 acquired	 in	 a	 context	 where	 a	 set	 of	 target	 variables	 has	 been	
systematically	manipulated	 by	 the	 investigator	 (e.g.,	 randomized	 clinical	 trials	 with	 placebo	 group	
and	active	treatment	group).	Precision	medicine	 in	psychiatry	 is	however	 likely	to	exploit	especially	
observational	data	(e.g.,	blood	and	metabolic	samples,	movement	and	sleeping	patterns,	EEG,	brain	
scans,	 and	 genetic	 variants)	 that	 were	 acquired	 without	 a	 carefully	 controlled	 influence	 in	 an	
experimental	setup	and	to	which	machine	learning	tools	may	be	more	closely	tuned	(e.g.,	18,	25,	26).	
	
v)	 Handle	 many	 outcomes:	 Machine	 learning	 is	 also	 a	 pertinent	 choice	 for	 comparisons	 between	
possible	 diagnoses	 and	 other	 multi-outcome	 settings.	 Classical	 significance	 testing	 is	 traditionally	
used	to	decide	between	two	possible	outcomes,	expressed	in	the	null	and	alternative	hypothesis,	by	
considering	the	probability	of	obtaining	an	equal	or	more	extreme	effect	 in	the	data	under	the	null	
hypothesis	 (27).	 This	 is	 often	 used	 in	 group	 analysis	 to	 formally	 determine	 a	 scientifically	 relevant	
difference	 between	 healthy	 subjects	 (i.e.,	 typically	 corresponding	 to	 the	 null	 hypothesis)	 and	
psychiatric	patients	as	defined	by	a	DSM	or	ICD	category	(i.e.,	typically	the	alternative	hypothesis),	or	
when	comparing	a	placebo	treatment	(i.e.,	null	hypothesis)	against	a	new	treatment	(i.e.,	alternative	
hypothesis).	In	everyday	practice	on	the	psychiatric	wards,	the	more	challenging	question	is	probably	
not	whether	a	patient	has	a	mental	disease	or	not	but	the	differential	diagnosis	between	a	number	
of	 likely	 disease	 categories	 ---	 the	 trans-diagnostic	 setting.	 Analogously,	 whether	 a	 patient	 needs	
treatment	 or	 not	 is	 routinely	 an	 easier	 clinical	 decision	 than	 choosing	 between	 a	 number	 of	
competing	 treatment	 options.	 Treatment	 response	 prediction	 is	 rarely	 a	 binary	 yes-or-no	 decision	
and	requires	consideration	of	several	treatment	options	in	the	same	statistical	analysis.	
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Machine	 learning	 is	 well	 suited	 to	 this	 goal	 in	 the	 form	 of	multi-class	 prediction	 and	multi-task	
learning	 (26,	 28,	 29),	 unlike	 many	 approaches	 for	 statistical	 significance	 and	 tests	 of	 group	
differences.	Most	machine	 learning	approaches	 that	are	applicable	when	aiming	to	distinguish	 two	
groups	 or	 two	 treatment	 options	 can	 be	 readily	 extended	 to	 considering	 a	 range	 of	 possible	
outcomes.	 For	 instance,	 quantitative	 brain	 measurements	 from	 one	 patient	 can	 be	 fed	 into	
prediction	models	 to	 infer	 a	 probabilistic	 stratification	 not	 only	 over	 several	 differential	 diagnoses	
and	over	many	 candidate	 treatment	options,	 but	 also	 risk	outcomes,	or	possible	 long-term	clinical	
prognoses	 (e.g.,	 full	 recovery	 versus	 partial	 residuals	 versus	 severe	 chronic	 illness).	 Additionally,	
applying	 learning	 algorithms	 to	 compare	 patients	 versus	 controls	 does	 not	 allow	 evaluating	 how	
specific	 an	 achieved	 prediction	 is	 for	 the	 given	 psychiatric	 group	 (24).	 Besides	 the	 advantage	 of	
replacing	 artificial,	 mutually	 exclusive	 dichotomies	 by	 predicting	 several	 outputs	 in	 concert,	 the	
prediction	 accuracy	 does	 also	 often	 improve	when	 statistical	 strength	 can	 be	 shared	 between	 the	
variation	in	the	data	associated	with	the	different	outcomes	(30).	In	sum,	there	are	clear	incentives	
and	 readily	 applicable	 statistical	 tools	 to	 go	 beyond	 group-level	 comparisons	 à	 la	 normal	 versus	
diseased	 (31,	 32).	 Importantly,	 machine	 learning	 is	 naturally	 suited	 for	 choosing	 between	 a	
potentially	large	number	of	possibilities	in	a	single	patient	and	ranking	the	possibilities	according	to	
pertinence.	This	is	the	case	in	the	trans-diagnostic	setting	where	the	pertinence	of	several	psychiatric	
diagnoses	needs	to	be	predicted	simultaneously	by	one	statistical	model.	
	
vi)	 Explore	 manifolds	 in	 complex	 data:	 Besides	 the	 intricacies	 of	 considering	 several	 diagnostic	
categories	at	once,	the	diagnostic	categories	themselves	have	repeatedly	been	called	 into	question	
due	 to	 their	 lack	of	neurobiological	 validity	and	clinical	predictability	 (1,	2).	The	disease	definitions	
cataloged	in	the	DSM	and	ICD	manuals	do	not	always	align	well	with	new	behavioral,	neuroscientific,	
and	 genetic	 evidence	 (Fig.	 1).	 Psychiatric	 disorders	 have	 been	 defined	 in	 the	DSM	 and	 ICD	with	 a	
focus	 on	 ensuring	 effective	 communication	 of	 diagnoses	 (i.e.,	 inter-rater	 reliability)	 between	
clinicians	rather	than	the	goal	to	capture	natural	kinds	in	biological	reality	(1).	Autism,	schizophrenia,	
and	an	 increasing	number	of	 other	psychiatric	 diseases	 are	 suspected	 to	be	 spectrum	disorders	 ---	
heterogeneous	 etiological	 and	 pathophyisiological	 factors	 being	 summarized	 under	 the	 same	
umbrella	 term	 (33,	 34).	 This	 conceptualization	 is	 also	 more	 compatible	 with	 a	 smooth	 transition	
between	healthy	and	psychiatrically	diagnosed	 individuals.	Machine	 learning	offers	a	rich	variety	of	
tools	that	readily	lend	themselves	to	endophenotype	modeling.	
Among	 many	 clinicians	 and	 researchers,	 there	 is	 hence	 a	 growing	 wish	 to	 supplement	 discrete	
disease	definitions	in	form	of	categories	with	a	continuous,	dimensional	symptom	system.	To	satisfy	
the	need	to	cut	across	diagnostic	boundaries,	the	Research	Domain	Criteria	(RDoC)	initiative	(35)	has	
been	 launched	 as	 a	 translational	 program	 to	 elucidate	 the	 hidden	 structure	 underlying	
psychopathology.	 By	 synergistic	 integration	 of	 self-reports,	 neuropsychological	 tests,	 brain	
measurements,	 and	 genetic	 profiles,	 RDoC	 wants	 to	 "better	 understand	 basic	 dimensions	 of	
functioning	 [...]	 from	normal	 to	abnormal"	 (National	 Institute	of	Mental	Health)	without	 relying	on	
presupposed	 disease	 definitions.	 The	 discovered	 fundamental	 dimensions	 of	 behavior	 and	 its	
disturbances	are	expected	 to	motivate	new	research	approaches	aimed	at	 re-formating	psychiatric	
nosology.	RDoC	thus	recommends	going	from	scientific	evidence	to	organically	deriving	new	disease	
factors.	This	 framework	thus	contrasts	the	dominant	agenda	 in	psychiatric	research	that	goes	from	
disease	 categories	defined	based	on	 the	DSM	and	 ICD	 to	 generating	 scientific	 evidence.	 The	RDoC	
approach	 is	 conceptually	 compatible	 with	 the	 fact	 that	 psychiatric	 patients	 exhibit	 clusters	 of	
psychopathological	 symptoms	 and	 that	many	 symptoms	 are	 shared	 among,	 rather	 than	 unique	 to	
different	 psychiatric	 disorders.	 RDoC	 is	 also	 naturally	 compatible	 with	 the	 accumulating	 evidence	
that	 risk	 alleles	 are	 partly	 shared	 between	 psychiatric	 disorders	 (36),	 while	 different	 sets	 of	 risk	
alleles	can	lead	to	an	identical	psychiatric	phenotype	(37).	
Of	 note,	 this	 renewed	 focus	 on	 fundamental	 building	 blocks	 of	 mental	 disturbance	 finds	 a	 direct	
correspondence	 in	 the	 long-standing	 focus	 of	 the	machine	 learning	 community	 on	 representation	
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learning	 for	discovering	hidden	structure	 in	 complex	data	 (38).	 In	particular,	 the	multi-dimensional	
conception	underlying	the	RDoC	initiative	is	reminiscent	of	the	notion	of	manifolds	that	is	common	in	
the	machine	learning	field	(9).	 In	a	setting	with	possibly	many	high-resolution	measurements	(brain	
scans,	 sequenced	 genome,	 etc.),	 a	 manifold	 describes	 coherent	 low-dimensional	 directions	 of	
relevant	variation	 in	 the	data.	Here,	members	of	a	 coherent	 class	would	be	expressed	as	 "a	 set	of	
points	 associated	with	 a	 neighborhood	 around	 each	 point"	 (9).	 In	 psychiatry,	 the	manifold	 notion	
corresponds	 to	 the	 hope	 that	 the	 nature	 of	 psychiatric	 disorders	 and	 their	 complex	 relationships	
could	be	described	effectively	 in	a	small	number	of	hidden	dimensions:	each	a	distinct	direction	of	
variation	 in	heterogeneous	data	sources.	Variation	captured	across	behavioral,	experiential,	neural,	
and	 genetic	measurements	 with	 tens	 of	 thousands	 of	 input	 variables	 can	 hopefully	 be	 effectively	
expressed	 along	 a	 manifold	 that	 concerns	 only	 a	 much	 smaller	 number	 of	 yet-to-be-discovered	
disease	dimensions.	
	
Indeed,	machine	learning	has	a	rich	legacy	of	algorithm	developments	that	can	now	be	repurposed	
to	automatically	extract	manifolds	from	data	describing	behavior,	life	experience,	brain,	or	genetics.	
Representation	 learning	algorithms	operate	on	 the	assumption	 that	 the	measured	data	have	been	
generated	by	a	set	of	underlying	constituent	 factors.	Unfortunately,	however,	many	currently	used	
traditional	 clustering	 algorithms,	 such	 as	 hierarchical	 and	 k-means	 clustering,	 share	 the	
inconvenience	 to	 assign	 each	 individual	 exclusively	 to	 one	 cluster	 (so-called	 "winner-takes-all"	
assumption).	 This	 biologically	 and	 clinically	 implausible	 statistical	 assumptions	 can	 be	 relaxed	 by	
recourse	 to	 latent	 factor	models	 (9,	 ch.	13),	 including	 latent	Dirichlet	allocation	 (25),	autoencoders	
(39),	 and	many	 other	 dictionary	 learning	 procedures.	 Latent	 factor	models	 can	 readily	 uncover	 an	
underlying	 manifold	 of	 hidden	 directions	 of	 variation	 by	 assigning	 each	 individual	 to	 each	 of	 the	
clusters	to	different	degrees.	Technically,	the	same	manifold	dimension,	reflecting	a	distinct	disease	
process,	 is	 thus	allowed	to	contribute	 in	nuanced	ways	to	several	psychiatric	disorders	with	clinical	
pictures	as	diverse	as	schizophrenia,	autism,	and	bipolar	disorder.	Thus,	given	the	prevailing	lack	of	
objective	 markers	 in	 psychiatry,	 there	 is	 merit	 in	 revealing,	 formalizing,	 and	 clinically	 exploiting	
currently	unknown	inter-individual	variation.	
	
For	 a	 long	 time,	 knowledge	 generation	 in	 basic	 neuroscience	 and	 clinical	 decision-making	 in	
psychiatry	 has	 been	 dominated	 by	 classical	 statistics	 with	 formal	 tests	 for	 group	 differences	 in	
frequently	 small	 samples.	 Machine	 learning	 methods	 however	 better	 appeal	 to	 the	 ambitions	 of	
precision	psychiatry	because	they	can	directly	translate	complex	pattern	discovery	in	“big	data”	into	
clinical	relevance.	For	most	learning	algorithms,	it	is	standard	practice	to	estimate	the	generalization	
performance	to	other	samples	by	empirically	cross-validating	the	trained	algorithms	on	fresh	data;	in	
this	case,	 individual	subjects.	This	stands	in	stark	contrast	to	classical	statistical	inference	that	seeks	
to	 reject	 the	 null	 hypothesis	 by	 considering	 the	 entirety	 of	 a	 data	 sample	 (27);	 in	 this	 case,	 all	
available	subjects.	 In	the	inferential	framework,	the	desired	relevance	of	a	statistical	relationship	in	
the	general	population	 is	ensured	by	formal	mathematical	proofs	and	 is	not	commonly	ascertained	
by	 explicit	 model	 evaluation	 on	 independent	 data	 (10,	 27).	 It	 will	 be	 of	 growing	 importance	 that	
many	 traditionally	 used	 tools	 testing	 for	 statistical	 significance	 are	 categorically	 incapable	 of	
affording	individual-level	model	predictions	---	a	cornerstone	for	personalized	medicine.	
	
Challenges	
Many	reasons	speak	 in	 favor	of	extending	machine	 learning	techniques	to	psychiatric	 research	and	
practice.	The	flipside	of	the	coin	is	that	there	are	still	a	number	of	obstacles	to	overcome:	
i)	Reproducibility:	Prototyping,	 iteratively	 improving,	 and	benchmarking	machine	 learning	pipelines	
involves	many	 complicated	 and	 inter-dependent	 choices.	 Such	multistep	 workflows	 are	 becoming	
challenging	to	fine-tune	manually;	hence	requiring	computer	programming	skills	that	will	probably	be	
in	 increasing	 demand.	 The	 flexibility	 of	 machine	 learning	 pipelines	 is	 raising	 the	 concern	 that	
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obtained	findings	might	less	reliably	replicate	in	later	studies	(40,	p.	185).	Successful	deployment	of	
predictive	models	on	 the	 clinical	ward	may	 require	 seamless	exchange	of	predictive	models	 in	 the	
research	community.	Once	acceptance	for	model	sharing	is	gained	and	effective	platforms	are	set	up,	
the	prediction	performance	of	 a	model	 can	undergo	 further	 validation	at	different	 levels	 (24):	 The	
final	 predictive	 models	 should	 pass	 the	 prospective	 test	 of	 new	 subjects	 in	 other	 research	
laboratories,	persevere	across	data	acquisition	means	(e.g.,	brain	scanners	from	Siemens,	Philips,	and	
GE),	 across	 geographic	 locations	 (e.g.,	 USA,	 Europe,	 and	 Asia)	 and	 across	 populations	 (e.g.,	 same	
mental	 disorder	with	 different	 comorbidity	 profiles),	 as	well	 as	 for	 different	 success	metrics	 (e.g.,	
sensitivity	 and	 specificity)	 and	 different	 clinical	 settings	 (e.g.,	 rural	 practitioner	 versus	 university	
hospital).	 In	 the	 future,	 a	 predictive	 model	 could	 improve	 step	 by	 step	 through	 annotation	 and	
modification	 in	 various	 laboratories	 in	 a	 cost-effective	 cumulative	 collaboration	 (24).	 Moreover,	
clinical	 biomarkers	 derived	 from	 genetics	 or	 brain-imaging	 will	 probably	 be	 accredited	 through	
randomized	clinical	trials,	like	other	treatment	candidates	for	psychiatry.	
ii)	 Data	 availability:	 The	 primary	 limitation	 for	 deploying	 state-of-the-art	 machine	 learning	 to	
personalize	 psychiatric	 care	 is	 probably	 the	 size	 of	 today’s	 datasets	 (i.e.,	 number	 of	 subjects)	 and	
their	 insufficient	 phenotypic	 descriptions	 (e.g.,	 medical	 history,	 comorbidities,	 progression	 in	
symptoms,	 treatment	 and	 response).	 A	 recent	 statement	 claimed	 that	 the	 "field	 of	mental	 health	
captures	arguably	the	largest	amount	of	data	of	any	medical	specialty"	(41).	However,	compared	to	
some	 non-medical	 research	 domains,	 psychiatric	 research	 is	 still	 far	 from	 the	 sample	 sizes	 of	 n	 >	
1,000,000	where	 the	 predictive	 power	 of	 the	 currently	most	 successful,	 yet	most	 data-demanding	
models	has	been	showcased	(9).	Thousands	of	observations	per	category	(e.g.,	brain	scans	or	genetic	
profiles	 of	 responders	 to	 one	 specific	 drug	 treatment)	 are	 typically	 required	 to	 reach	 reasonable	
prediction	 accuracy	 with	 so-called	 “deep	 neural-networks”	 (9),	 while	 these	 models	 repeatedly	
achieved	 supra-human	 performance	 with	 millions	 of	 observations.	 Even	 ongoing	 prospective	
population	studies,	such	as	the	burgeoning	UK	Biobank,	aim	at	brain	scans	from	"only"	n	=	100,000	
participants	to	be	completed	in	2022.	Similarly,	genome-wide	analyses	on	a	specific	phenotype	have	
rarely	 reached	 sample	 sizes	 of	more	 than	 n	 =	 100,000	 participants.	 Besides	 limited	 data	 quantity,	
exploiting	 emerging	 machine	 learning	 technologies	 is	 hindered	 by	 insufficient	 specificity	 and	
granularity	 of	 the	 participants'	 behavioral	 information.	 On	 the	 one	 hand,	 many	 phenotypes	 of	
interest	 do	 not	 vary	 enough	 across	 subjects	 in	 general-purpose	 datasets.	 On	 the	 other	 hand,	
deploying	current	machine	learning	for	successful	subject-level	prediction	of	practically	useful	clinical	
endpoints	 will	 probably	 depend	 on	 datasets	 with	 rich	 and	 meticulously	 acquired	 patient	
documentation	from	various	time	points.	Soon,	high-throughput	predictive	models	may	be	satisfied	
by	the	increasing	digitalization	of	everyday	life	by	ubiquitious	electronic	sensors	(42).		
	
iii)	Data	management:	Over	 the	 last	 10	 years,	 growing	 sample	 sizes	were	enabled	by	national	 and	
international	 consortia	 to	 accumulate,	 curate,	 and	 distribute	 data	 across	 research	 groups,	
exemplified	 by	 the	 Autism	 Brain	 Imaging	 Data	 Exchange	 (ABIDE)	 and	 Alzheimer’s	 Disease	
Neuroimaging	Initiative	(ADNI).	An	important	prerequisite	resides	in	the	willingness	to	embrace	the	
values	and	habits	of	the	open-science	movement	(43),	potentially	prompting	re-calibration	between	
society’s	good	and	citizens’	rights.	While	some	investigators	deem	restricted	access	to	research	data	
unethical,	data	sharing	also	invokes	privacy	concerns	(44).	For	instance,	a	participant’s	face	could	be	
recognized	from	anatomical	brain	scans,	but	this	sensible	information	can	be	automatically	removed	
by	 de-facing	 techniques.	 Similarly,	 the	Human	Connectome	Project	 (HCP)	 has	 adopted	 a	multi-tier	
access	 policy:	 Most	 data	 are	 openly	 available	 from	 all	 subjects,	 whereas	 access	 to	 their	 sensitive	
information	 is	 controlled.	 As	 another	 trend,	 the	 same	 dataset	 can	 be	 disseminated	 in	 different	
variants:	 from	sharing	only	3D	coordinates	of	neural	activity	changes,	over	precomputed	aggregate	
data	 as	 statistical	 summaries	 to	 preprocessed	 or	 full	 raw	 data	 (21,	 44).	 Further,	 retrieving	 an	
extensive	dataset	requires	considerable	transmittion	bandwidth	and	may	be	infeasible	or	unallowed.	
The	ENIGMA	consortium	has	demonstrated	large-scale	analysis	of	data	from	>1000	subjects	stored	in	
distant	 research	 centers	 using	 distributed	 model	 fitting	 (45).	 Emerging	 means	 for	 decentralized	
model	building	can	enable	large	federated	statistical	analysis	precluding	the	need	for	data	pooling	in	
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a	 single	 location.	 Consequently,	 agreement	 on	 machine-readable	 data	 structures	 will	 grow	 in	
importance	(46).	
	
iv)	 Heterogeneous	 and	 incomplete	 data:	 A	 first	 generation	 of	 data	 initiatives	 (e.g.,	 ABIDE,	 ADNI,	
ENIGMA)	 were	 retrospective	 collections	 of	 independently	 acquired	 data	 from	 different	 clinical	
centers.	Such	data	repositories	 typically	vary	 in	data	quality,	acquisition	parameters,	hardware	and	
software	 versions,	 preprocessing	 procedures,	 artifact	 occurrence	 and	 quality	 control,	 used	
psychological	assessments	and	clinical	questionnaires,	missing	data,	and	population	aspects.	Across-
site	 heterogeneity	may	 explain	 why,	 counter-intuitively,	 predictive	model	 performance	 have	 been	
repeatedly	 reported	 to	 decrease	 as	 the	 available	 neuroscience	 data	 increases	 (24).	 A	 second	
generation	of	data	 initiatives	 (e.g.,	HCP	and	UK	Biobank)	 realized	prospective	collections	 that	early	
convened	 on	 how	 to	 standardize	 data	 acquisition.	 Ensuing	 repositories	 offer	 higher	 data	
comparability	 due	 to	 efforts	 including	 calibrated	 acquisition	 conditions,	 staff	 training,	 or	 traveling	
experts.	 Of	 note,	 homogenizing	 data	 acquisition	 and	 analysis	 can	maximize	 group	 differences	 and	
alleviate	confound	problems,	whereas	homogenizing	population	samples	may	not	be	optimal	 in	all	
cases.	A	majority	of	 clinical	 studies	 recruits	patient	 samples	based	on	 tight	 inclusion	and	exclusion	
criteria.	 Such	 handpicked	 subject	 groups	 (e.g.,	 excluding	 frequent	 comorbidities	 of	 a	 disease)	 are	
often	less	representative	of	the	broader	population.	Derived	predictive	models	may	not	perform	well	
on	the	genuinely	heterogeneous	patients	on	the	psychiatric	ward.	Hence,	a	balance	must	be	 found	
between	conservative	manual	 selection	of	 samples	with	convincing	model	performance	and	 liberal	
samples	more	representative	of	clinical	reality.	
	
v)	Longitudinal	data:	Retrospective	data	collections	typically	lend	themselves	more	to	cross-sectional	
analysis,	while	prospectively	collected	data	are	often	suitable	for	longitudinal	analysis.	Most	machine	
learning	 approaches	 and	 their	 clinical	 applications	 currently	 focus	 on	 cross-sectional	 findings.	
Computational	psychiatry	research	may	bear	a	blind	spot	regarding	disease	trajectories	and	longer-
term	health	outcomes	(17),	despite	the	time-varying	nature	of	many	mental	disorders.	A	promising	
avenue	 to	 accumulate	 massive	 longitudinal	 data	 may	 be	 offered	 by	 technical	 devices	 carried	 by	
subjects	 (42),	 a	 rationale	 that	 has	 already	 energized	 many	 commercial	 health	 companies.	 For	
instance,	voice	data	from	smartphones	and	connected	technologies	could	enable	early	detection	of	
healthcare	 events,	 such	 as	 thought	 disorders,	 depressive	 episodes,	 or	 suicide	 attempts.	 More	
generally,	 digital	 sensors	 are	 becoming	 ubiquitous	 and	 are	well	 positioned	 to	 continously	monitor	
diverse	behaviors,	 including	sleep	patterns,	communication	habits,	as	well	as	gait	and	geographical	
movement.	This	may	enable	evolving	machine	learning	models	that	capture	which	factors	contribute	
to	a	patient’s	 symptom	dynamics	across	 time.	 In	addition	 to	privacy	 concerns,	ditigital	 sensors	are	
subject	to	constant	change	in	hardware	and	software,	which	increases	heterogeneity	in	the	acquired	
longitudinal	data.	
	
vi)	Confounding:	Accumulating	observational	human	data	 is	often	cheaper	and	easier,	while	 lack	of	
experimental	 protocols	 exacerbates	 control	 of	 confounding	 influences	 (47).	 Essentially,	 the	
prediction	performance	becomes	 inflated	 if	 the	training	data	used	for	model	 fitting	and	the	testing	
data	 are	 somehow	 mutually	 dependent,	 even	 if	 contaminated	 in	 subtle	 ways.	 Researchers	 are	
challenged	 to	 identify	 and	 account	 for	 influences	 unintentionally	 contributing	 to	 high	 prediction	
accuracies,	 including	age,	gender,	culture,	ethnicity,	 smoking,	caffeine,	movement	effects	 (e.g.,	eye	
blinks),	physiological	noise	(e.g.,	respiration	and	heart	beat),	and	medication	use.	Confounding	gets	
more	complicated	in	continuously	updated	models:	A	biased	predictive	model	could	 lead	to	clinical	
action	that	further	increases	the	existing	bias	---	driving	a	feedback	loop	with	self-fulfilling	prophecies	
(48).	 Sociologically,	 investigators	 are	 also	 often	 restricted	 to	 hospitalized	 population	 samples.	 Bias	
may	 inadvertently	 arise	 because	 clinical	 research	 typically	 recruits	 subjects	 with	 exposure	 to	
psychiatric	institutions,	rather	than	never-diagnosed	individuals	with	mental	problems.	For	instance,	
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high-functioning,	subclinical	schizophrenics,	never	 in	contact	with	a	psychiatrist,	may	systematically	
evade	research	efforts.	Finally,	some	confounding	issues	might	be	revealed	and	alleviated	by	shifting	
towards	more	nuanced	prediction	in	a	multi-outcome	settings,	such	as	simultaneously	distinguishing	
schizophrenia,	schizoaffective	disorder,	autism,	bipolar	and	personality	disorders.	
	
Conclusion	
The	devastating	collateral	damage	and	soaring	costs	of	psychiatric	disease	prompt	a	global	challenge	
for	our	societies	(49).	Whether	or	not	personalized	medicine	can	be	realized	to	enhance	psychiatric	
care	 is	 largely	 a	 statistical	 question	 at	 its	 heart.	 For	 many	 decades,	 the	 group	 has	 served	mental	
health	investigators	as	the	primary	working	unit.	Facilitated	acquisition	of	always	more	detailed	and	
diverse	information	on	psychiatric	patients	is	now	bringing	another	working	unit	within	reach	---	the	
single	 patient.	 Rather	 than	 preassuming	 existence	 of	 disease	 categories	 and	 formally	 verifying	
prespecified	neurobiological	hypotheses,	an	increasingly	attractive	alternative	goal	is	to	let	the	data	
guide	 the	 investigation.	 Following	 the	 new	 data	 richness	 and	 changing	 research	 questions,	 some	
long-trusted	statistical	methods	may	be	superseded	as	the	best	tool	in	the	box.	
Machine	 learning	 offers	 a	 statistical	 culture	 that	 can	 readily	 appreciate	 the	 smooth	 transition	
between	well-being	and	illness	as	well	as	the	foggy	boundaries	between	disease	categories.	Learning	
algorithms	 hold	 promise	 for	 the	 biologically	 grounded	 reconstruction	 of	 psychiatric	 disease	
descriptions	 by	 uncovering	 and	 leveraging	 inter-individual	 variation	 across	 behavior,	 experience,	
brain,	and	genetics.	Data-derived	disease	manifolds	can	transcend	the	traditional	disease	categories	
portrayed	in	the	DSM	and	ICD	that	today	govern	treatment	choice	and	prognosis	(24).	The	statistical	
properties	of	learning	algorithms	could	thus	enable	clinical	translation	of	empirically	justified	single-
patient	prediction	 in	a	 fast,	 cost-effective,	and	pragmatic	manner.	Patient-level	predictive	analytics	
might	help	psychiatry	 to	move	 from	strong	 reliance	on	 symptom	phenomenology	 to	catch	up	with	
biology-centered	decision-making	in	other	medical	specialities	(50).	
From	a	 larger	perspective,	mental	 health	 researchers	 struggle	 to	 verbalize	mechanistic	hypotheses	
for	psychiatric	disorders	at	the	most	pertinent	abstraction	level,	ranging	from	molecular	histone-tail	
methylation	 in	 the	 cell	 nucleus	 to	 urbanization	 trends	 in	 society	 as	 a	 whole.	 This	 epistemological	
challenge	 highlights	 more	 human-independent	 pattern	 learning	 algorithms	 as	 an	 under-exploited	
research	 avenue.	 Learning	 algorithms	 can	 automatically	 identify	 disease-specific	 biological	 aspects	
that	achieve	intrinsically	valid	and	immediately	useful	clinical	predictions.	Ultimately,	by	allying	with	
recent	statistical	technologies	we	may	more	likely	impact	mental	disease	that	arises	at	the	interplay	
between	genetic	endowment	and	life	experience	---	both	of	which	are	unique	to	each	individual.	
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Figure	 1:	 Current	 challenges	 for	 precision	 medicine	 in	 psychiatry	 and	 possible	 solutions	 from	
machine	learning	
A)	 Basic	 and	 clinical	 psychiatric	 research	 frequently	 investigates	 a	 given	 patient	 population	 by	 group	
comparison	 against	 the	 healthy	 population,	 possibly	 creating	 artificial	 dichotomies.	 Many	 machine	 learning	
approaches	 can	 naturally	 compare	 observations	 from	 a	 number	 of	 groups	 in	 the	 same	 statistical	 estimation	
(i.e.,	multi-class	prediction;	see	also	Table	1).	B)	The	diagnostic	categories	 in	the	 ICD	and	DSM	manuals	were	
designed	to	reliably	describe	symptom	phenomenology	and	are	 frequently	 incongruent	with	new	behavioral,	
neural,	and	genetic	research	evidence.	Machine	learning	methods	can	automatically	extract	currently	unknown	
patterns	 of	 variation	 in	 individuals	 (i.e.,	 manifold)	 simultaneously	 from	 heterogeneous	 data	 that	 cut	 across	
traditional	 diagnoses.	C)	 Assigning	diagnostic	 categories	 to	patients	 ignores	 that	 different	pathophysiological	
mechanisms	(i.e.,	endophenotypes)	can	contribute	to	the	same	clinical	picture.	Instead	of	relying	on	categorical	
assignments,	biologically	defined	 subgroups	 can	be	described	by	 continuous	 contributions	of	 several	disease	
processes	 in	 graded	 degrees	 (i.e.,	 latent	 factor	models).	D)	 Psychiatric	 care	 often	 resorts	 to	 trial	 and	 error.	
Predictive	 models	 can	 improve	 patient	 care	 by	 earlier	 detection,	 treatment	 selection	 and	 adjustment,	 and	
inference	of	disease	trajectory.	After	a	machine	learning	algorithm	has	been	trained	in	extensive	data	(i.e.,	in-
sample),	 the	 trained	predictive	model	 can	be	used	 for	personalized	prediction	without	database	access	 (i.e.,	
out-of-sample).	Reprinted	with	permission	and	modified	from	(2).	
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Table	1:	Overview	of	mentioned	machine	learning	techniques	(in	order	of	appearance)	
	
Notion	 Purpose	
Supervised	learning	 Models	that	predict	a	discrete	outcome	(e.g.,	healthy	group	versus	control	group)	or	continuous	outcome	
(e.g.,	disease	severity	degrees)	from	measures	of	behavior	(e.g.,	questionnaire),	brain	(e.g.,	neural	activity),	
or	genetics	(e.g.,	single	nucleotide	polymorphisms)	
Data	have	the	form:	features	𝑋	(𝑛	subjects	x	𝑝	variables)	and	target	variable	𝑦	(one	entry	for	each	subject)	
Example:	Estimate	patient	prognosis	based	on	genetic	profile.	
Unsupervised	learning	 Models	that	discover	structure	that	is	coherently	present	in	the	𝑝	variables	across	subjects.	
Data	have	the	form:	features	𝑋	(𝑛	subjects	x	𝑝	variables),	but	no	target	variable	𝑦.	
Example:	Reveal	biological	disease	subgroups	in	patients	based	on	genetic	profile.	
Clustering	 A	class	of	unsupervised	methods	that	uses	a	certain	criterion	to	segregate	a	set	of	elements	into	a	number	
of	groups	according	to	their	measured	similarity.	Many	clustering	models	perform	hard	assignments:	the	
groups	are	non-overlapping,	with	each	element	associated	with	only	one	group	(i.e.,	‘winner-takes-all’	
assumption).	
Example:	k-means	clustering,	hierarchical	clustering,	spectral	clustering,	density-based	spatial	clustering	
(DBSCAN)	
Dimensionality	reduction	 Re-expressing	a	set	of	observations	in	terms	of	their	underlying	essential	patterns.	
Support	vector	machines	 A	supervised	model	that	performs	prediction	based	on	identifying	observations	in	the	data	that	are	typical	
for	the	categories	to	be	distinguished.	
Neural-network	algorithms	 A	supervised	model	that	performs	prediction	based	on	a	non-linear,	multi-layer	variant	of	linear	regression.	
“Deep”	neural-network	are	a	modern	version	with	a	higher	number	of	non-linear	processing	layers.	
Cross	validation	 A	two-step	procedure	used	as	the	de-facto	standard	to	estimate	the	capacity	of	a	pattern	learning	model	to	
extrapolate	to	future	data	samples.	First,	the	predictive	model	is	fitted	on	training	data	and,	second,	its	
generalization	performance	is	evaluated	on	test	data	(out-of-sample).	The	process	is	repeated	for	different	
splits	of	the	data	(often	5	or	10	times).	
In-sample	estimate	 Prediction	performance	measured	in	the	same	data	that	was	also	used	to	fit	the	model.	
Example:	Most	applications	of	linear	regression	in	biomedical	research	exclusively	consider	in-sample	
estimates,	without	considering	out-of-sample	estimates.	
Out-of-sample	estimate	 Prediction	performance	measured	in	new	data	that	was	not	used	to	fit	a	model.	
Example:	In	machine	learning,	it	is	the	core	metric	of	how	successful	extrapolation	of	a	derived	pattern	to	
new,	independent	data	is	quantified.	
Training	data	 A	model	is	fitted	to	identify	a	certain	pattern	from	a	larger	part	of	the	available	data.	
Test	data	 An	already	fitted	model	is	used	for	prediction	in	a	smaller	part	of	the	available	data.	
Multi-class	learning	 Applying	a	supervised	model	to	predict	an	outcome	𝑦	that	denotes	more	than	two	(possibly	hundreds	of)	
categories.	
Example:	Model	predicts	best	among	(many)	more	than	two	drug	treatment	options.	
Multi-task	learning	 Applying	a	supervised	model	to	simultaneously	predict	several	outcomes	𝑦1, 𝑦2,	…,		𝑦m.	
Example:	Model	uses	the	same	brain	scans	to	conjointly	predict	drug	treatment	options,	candidate	
diagnoses,	and	disease	trajectories.	
Manifolds	 The	statistical	goal	to	reveal	and	express	distinct	factors	that	collectively	underlying	a	set	of	observations.	
Example:	Everyday	objects	are	manifolds	in	a	3D	space	(e.g.,	a	flower),	although	there	is	a	variety	of	
perspectives	from	which	humans	can	gather	and	contemplate	information	about	an	object,	including	
vision,	audition,	touch,	smell,	and	many	others.	
Representation	learning	 Applying	models	that	can	automatically	extract	hidden	manifolds	from	data.	
Latent	factor	modelling	 A	class	of	unsupervised	methods	that	use	a	certain	criterion	to	stratify	a	set	of	elements	with	their	
respective	relationship	to	a	number	of	hidden	components	of	variation	so	as	to	maximize	between-
component	dissimilarity.	Many	latent	factor	models	perform	soft	assignments:	component	of	variations	are	
overlapping,	with	each	element	associated	to	each	component	to	a	certain	extent	(i.e.,	no	‘winner-takes-
all’	assumption).	
Example:	latent	Dirichlet	allocation,	autoencoders,	nonnegative	matrix	factorization	(NMF),	isomap,	t-
distributed	stochastic	neighbor	embedding	(t-SNE)	
K-means	clustering	 A	popular	clustering	model	that	partitions	the	𝑝	variables	of	𝑋	into	𝑘	non-overlapping	groups.	
Example:	Use	genetic	information	to	group	mammels	into	human	and	non-human	primates	(𝑘 = 2).	
Hierarchical	clustering	 A	popular	clustering	model	that	successively	builds	a	nested	tree	where	the	𝑝	variables	of	𝑋	are	portioned	
into	𝑘	always	more	fine-grained	non-overlapping	groups.	All	clustering	solutions	from	𝑘 = 1	group	to	𝑘 =𝑛	groups	are	often	computed.	
Example:	Use	genetic	information	to	group	mammels	(𝑘 = 1)	into	human	and	non-human	primates	(𝑘 =2),	which	are	then	grouped	into	humans,	apes,	and	monkeys	(𝑘 = 3),	and	so	forth.	
Latent	Dirichlet	allocation	 A	latent	factor	model	that	stratifies	count-like	data	into	overlapping	components	of	variation.	
Example:	Extract	coherent	combinations	of	number	of	times	(positive	discrete	numbers)	words	occurred	
during	an	unstructured	clinical	interview.	
Autoencoders	 A	latent	factor	model	that	stratifies	continuous	data	into	overlapping	components	of	variation.	
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Example:	Extract	coherent	combinations	of	item	scores	from	structure	clinical	questionnaire	
(positive/negative	non-discrete	numbers).	
Dictionary	learning	 Super-class	of	many	clustering	models	and	latent	factor	models.	
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